AstraZeneca PLC (LON:AZN)
14,318p+1.82%
Spriggl Score: Strong— sign in to explore; full breakdown with Premium
Last 30 trading days
Spriggl AI Verdict
“Oncology dominance and rare disease strength justify premium price despite China regulatory risks.”
Sign up free to read the full investment thesis, bull case, bear case and what to watch.
About AstraZeneca PLC
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Cr…
- Sector:
- Healthcare
- Industry:
- Drug Manufacturers - General
- Market Cap:
- £218.1B
Recent dividends
- 19 Feb 2026160p
- 7 Aug 202576.70p
- 20 Feb 2025168p
Get the full Spriggl analysis — free
A free Spriggl account gets you the screener, a watchlist, AI verdicts and a free full report every day — across AstraZeneca PLC and 1,500+ UK and US stocks. The full score breakdown and AI analysis come with Premium.
Start free